BlackRock Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

BlackRock Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4K	Hold	25	–	–	﹤0.01%	3642
2016 Q3	$6K	Sell	25 -4	-14%	-$1.46K	﹤0.01%	3625
2016 Q2	$26K	Sell	29 -9	-24%	-$9.93K	﹤0.01%	3384
2016 Q1	$35K	Buy	38 +12	+46%	+$11.8K	﹤0.01%	3266
2015 Q4	$36K	Sell	26 -12	-32%	-$20.9K	﹤0.01%	3313
2015 Q3	$64K	Buy	38 +4	+12%	+$8.24K	﹤0.01%	3255
2015 Q2	$73K	Buy	34 +17	+100%	+$32.9K	﹤0.01%	3261
2015 Q1	$32K	Buy	17 +5	+42%	+$11K	﹤0.01%	3345
2014 Q4	$29K	Buy	+12	New	+$28.5K	﹤0.01%	3406

Other funds holding ELDN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Advisors's ELDN Position: Q4 2016 in Review

BlackRock Advisors held its Eledon Pharmaceuticals (ELDN) position steady in Q4 2016 at 25 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #3642.

BlackRock Advisors first reported a position in ELDN in Q4 2014 and has held it in 9 quarters since. The position peaked at $73K in Q2 2015. 42 funds tracked by Wall St. Rank hold ELDN as of Q4 2016.

BlackRock Advisors held 25 shares of Eledon Pharmaceuticals worth $4K as of Q4 2016.
BlackRock Advisors left its Eledon Pharmaceuticals share count unchanged in Q4 2016.
Eledon Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3642 holding.
BlackRock Advisors first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 9 quarters since.
BlackRock Advisors's Eledon Pharmaceuticals position peaked at $73K in Q2 2015.
42 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.